Recent Updates
Recently added Catalysts

Intranasal challenge drug

Phase 3

Heroin Dependence | Small molecule | Other |Indivior Pharmaceuticals, Inc.|Last Updated: Sep 8, 2017

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindACTIVE_CONTROLLEDBiomarker
Total Trials1
Total Enrollment27
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT01760473Reinforcing Effects of Intranasal (IN) Buprenorphine Versus Buprenorphine/NaloxonePHASE3 COMPLETED 27May 1, 2009Dec 1, 2014Sep 8, 20171 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Drug Self-administration
Throughout the testing sessions (approximately 9 weeks).

The maximum number of responses (clicks on a computer mouse) the participant was willing to perform in order to receive a dose of the intranasal challenge drug under investigation.

Secondary Endpoints
SOWS
Throughout the testing sessions (approximately 9 weeks).
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingDOUBLE
ModelCROSSOVER
PurposeBASIC_SCIENCE
Treatment Arms
ArmTypeDescription
Bup 8EXPERIMENTALIntranasal challenge drug: 8 mg of Buprenorphine administered intranasally.
Bup 16EXPERIMENTALIntranasal challenge drug: 16 mg of Buprenorphine administered intranasally.
Bup/Nal 8/2EXPERIMENTALIntranasal challenge drug: 8 mg of Buprenorphine administered intranasally with 2 mg of Naloxone.
Bup/Nal 8/8EXPERIMENTALIntranasal challenge drug: 8 mg of Buprenorphine administered intranasally with 8 mg of Naloxone.
Bup/Nal 8/16EXPERIMENTALIntranasal challenge drug: 8 mg of Buprenorphine administered intranasally with 16 mg of Naloxone.
Bup/Nal 16/4EXPERIMENTALIntranasal challenge drug: 16 mg of Buprenorphine administered intranasally with 4 mg of Naloxone.
HeroinACTIVE_COMPARATORIntranasal challenge drug: 24 mg of heroin administered intranasally.
PlaceboSHAM_COMPARATORIntranasal challenge drug: Intranasal lactose powder.
Naloxone 4 mgACTIVE_COMPARATORIntranasal challenge drug: Intranasal Naloxone 4mg.
Interventions
NameTypeDescription
Intranasal challenge drugDRUGEach of the experimental challenge drugs were administered intranasally to all participants in random order.
Unlock Study Design Details
Eligibility Criteria
Age Range21 Years — 45 Years
SexALL
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: * DSM IV criteria for heroin dependence * No major mood, psychotic, or anxiety disorder * Physically healthy * Able to perform study procedures * 21-45 years of age * Normal body weight * Current use of opioids in amounts and/or frequencies that meet or exceed those used in the ...

Countries:United States
Unlock Eligibility Criteria